Radionuclide News and Research

RSS

Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine.

4 Apr 2024

Urea-powered nanorobots reduce bladder tumors by 90% in mice

The research, which was conducted on mice, demonstrates how these tiny nanomachines are propelled by urea present in urine and precisely target the tumour, attacking it with a radioisotope carried on their surface.

16 Jan 2024

Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery

A study in Nature Nanotechnology reveals the potential of urease-powered nanobots to enhance bladder cancer treatment, showing a 90% tumor reduction in a mouse model using radioiodine-loaded nanobots for targeted therapy.

15 Jan 2024

Dual-action drug produces shows promising results in neuroendocrine tumor trial

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

22 Oct 2023

New consensus statement provides guidance for use of 177Lu-PSMA radionuclide therapy in mCRPC patients

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy.

5 Sep 2023

COST Connect: A platform for collaboration and progress in cancer research

Beating cancer is a major challenge for research and innovation in the coming years. By 2030, it is estimated that over 1.5 million people in the EU will succumb to cancer.

6 Jul 2023

New radionuclide-based agent offers hope for treating a variety of cancers

A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach.

27 Jun 2023

New technique shows potential to generically treat several kinds of cancer

Researchers led by Katsunori Tanaka at the RIKEN Cluster for Pioneering Research (CPR) in Japan and Hiromitsu Haba at the RIKEN Nishina Center for Accelerator-Based Science (RNC) have developed a new technique that has the potential to generically treat several kinds of cancer, with fewer negative side effects than currently available methods.

27 Jun 2023

Study opens new possibilities of tailoring radiopharmaceutical treatment to neuroendocrine cancer patients

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine cancer.

7 Apr 2023

New strategies to beat rare tumors of the adrenal gland

Only one in 100,000 people suffer from a pheochromocytoma, a tumor of the adrenal gland. If the tumor has already metastasized, a radioactive compound can be used to detect malignant cells that have spread to other parts of the body, and to irradiate them from the inside.

9 Feb 2023

Imaging method yields highly accurate and precise values of radionuclide organ uptake

Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation therapy that is delivered into or very close to the tumor.

16 Dec 2022

Novel molecular imaging radiotracer can precisely diagnose multiple cancers

A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

20 Nov 2022

Research reveals molecular pathways of aggressive cribriform prostate cancer

Cribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways.

26 Oct 2022

Duke biomedical engineers develop a two-pronged approach to treating pancreatic cancer

Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models.

21 Oct 2022

PSI researchers optimize a method for tumor diagnosis using radionuclides

Researchers at the Paul Scherrer Institute PSI, in collaboration with ETH Zurich, have optimized a method for tumor diagnosis using radionuclides.

5 Oct 2022

uPAR may be a promising target for therapy in patients with neuroendocrine neoplasms

A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms (NENs).

28 Sep 2022

Researchers develop new precision medicine technology for cancer immunotherapy

In recent years, great advances have been made in the development of new successful immunotherapies to treat cancer. CAR T-cell therapy and antibody treatments are two types of targeted immunotherapies that have revolutionized areas of cancer care.

28 Feb 2022

Combination treatment can effectively inhibit tumor growth

Researchers at the Paul Scherrer Institute PSI have tested various methods to check how effective they are in combatting certain types of cancer.

15 Dec 2021

$Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients$

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients.

29 Nov 2021

Study proves safety and effectiveness of novel radionuclide therapy for neuroendocrine neoplasms

A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients.

23 Nov 2021